New Classifications of Five Distinct “Sleep” Profi... ...
Science in the Age of AI | AI for Science Forum...
Ask the Heart Doctor | Heart Valve Disease and Sur...
High-speed imaging tracks live brain cell activity...
NAD⁺ restores memory in Alzheimer's disease models...
Mark Cuban: A Master Disrupter for American Health...
Teen girls facing the most adversity showed the biggest gain...
September 15,2026
Specialized imaging reveals hormone-driven brain changes...
September 14,2026
Submillimeter MRI reveals brain hubs that guide risky decisi...
September 12,2026
Risk of herpes zoster among breast cancer survivors in Japan...
September 11,2026
Three proteins help organs tailor shared circadian clock to ...
September 10,2026
Should you worry about melatonin and heart failure? The evid...
December 02,2025
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Today's News
GOSH BRC Showcase 2025 - Genomic medicine...
Can a twice-a-year shot help end the HIV...
Announcement of the 2025 Nobel Prize in ...
Reprogramming Stem Cells Could Cure Type...
Why MDMA did NOT get FDA approval...
More News
Fruquintinib provides meaningful benefit in refractory metastatic colorectal cancer

Fruquintinib provides meaningful benefit in refractory metastatic colorectal cancer

by Elana GotkineFor patients with refractory metastatic colorectal cancer, fruquintinib treatment yields a significant and clinically meaningful benefit in terms of overall survival, according to a st
World medicine December 05,2023
Fruquintinib provides meaningful benefit in refractory metastatic colorectal cancer

Fruquintinib provides meaningful benefit in refractory metastatic colorectal cancer

by Elana GotkineFor patients with refractory metastatic colorectal cancer, fruquintinib treatment yields a significant and clinically meaningful benefit in terms of overall survival, according to a st
World medicine December 05,2023
FDA approves lynparza for BRCA-mutated metastatic castration-resistant prostate cancer

FDA approves lynparza for BRCA-mutated metastatic castration-resistant prostate cancer

by Lori SolomonThe U.S. Food and Drug Administration approvedLynparza(olaparib) with abiraterone and prednisone (or prednisolone) for adult patients with deleterious or suspected deleterio
World medicine December 05,2023
FDA approves lynparza for BRCA-mutated metastatic castration-resistant prostate cancer

FDA approves lynparza for BRCA-mutated metastatic castration-resistant prostate cancer

by Lori SolomonThe U.S. Food and Drug Administration approvedLynparza(olaparib) with abiraterone and prednisone (or prednisolone) for adult patients with deleterious or suspected deleterio
World medicine December 05,2023
FDA approves Akeega for BRCA-positive metastatic prostate cancer

FDA approves Akeega for BRCA-positive metastatic prostate cancer

by Lori SolomonThe U.S. Food & Drug Administration has approvedAkeega(niraparib and abiraterone acetate) for the treatment of BRCA-positive metastatic castration-resistant prostate can
World medicine December 05,2023
FDA approves Akeega for BRCA-positive metastatic prostate cancer

FDA approves Akeega for BRCA-positive metastatic prostate cancer

by Lori SolomonThe U.S. Food & Drug Administration has approvedAkeega(niraparib and abiraterone acetate) for the treatment of BRCA-positive metastatic castration-resistant prostate can
World medicine December 05,2023
FDA provides accelerated approval of Talvey for multiple myeloma

FDA provides accelerated approval of Talvey for multiple myeloma

by Lori SolomonThe U.S. Food and Drug Administration has approvedTalvey(talquetamab-tvgs) for patients with relapsed or refractory multiple myeloma.Theaccelerated approvalis fo
World medicine December 05,2023
FDA provides accelerated approval of Talvey for multiple myeloma

FDA provides accelerated approval of Talvey for multiple myeloma

by Lori SolomonThe U.S. Food and Drug Administration has approvedTalvey(talquetamab-tvgs) for patients with relapsed or refractory multiple myeloma.Theaccelerated approvalis fo
World medicine December 05,2023
Epkinly granted accelerated FDA approval for lymphoma treatment

Epkinly granted accelerated FDA approval for lymphoma treatment

by Lori SolomonThe U.S. Food and Drug Administration has granted accelerated approval for Genmab'sEpkinly (epcoritamab-bysp)for relapsed or refractory diffuse large B-cell lymphoma (DL
World medicine December 05,2023
Epkinly granted accelerated FDA approval for lymphoma treatment

Epkinly granted accelerated FDA approval for lymphoma treatment

by Lori SolomonThe U.S. Food and Drug Administration has granted accelerated approval for Genmab'sEpkinly (epcoritamab-bysp)for relapsed or refractory diffuse large B-cell lymphoma (DL
World medicine December 05,2023
DNA repair discoveries hold promise for new approaches to cancer treatment

DNA repair discoveries hold promise for new approaches to cancer treatment

byNYU Langone HealthA depiction of the double helical structure of DNA. Its four coding units (A, T, C, G) are color-coded in pink, orange, purple and yellow. Credit: NHGRIDNA can be damaged by
World medicine December 05,2023
DNA repair discoveries hold promise for new approaches to cancer treatment

DNA repair discoveries hold promise for new approaches to cancer treatment

byNYU Langone HealthA depiction of the double helical structure of DNA. Its four coding units (A, T, C, G) are color-coded in pink, orange, purple and yellow. Credit: NHGRIDNA can be damaged by
World medicine December 05,2023
DNA discovery may assist in fight against aggressive cancer

DNA discovery may assist in fight against aggressive cancer

byUniversity of OtagoGraphical abstract. Credit:iScience(2023). DOI: 10.1016/j.isci.2023.106986In a significant development in the fight against fatal cancers, University of Otago re
World medicine December 05,2023
DNA discovery may assist in fight against aggressive cancer

DNA discovery may assist in fight against aggressive cancer

byUniversity of OtagoGraphical abstract. Credit:iScience(2023). DOI: 10.1016/j.isci.2023.106986In a significant development in the fight against fatal cancers, University of Otago re
World medicine December 05,2023
DNA test could broaden access to cervical cancer screening

DNA test could broaden access to cervical cancer screening

by Jade Boyd,Rice UniversityA low-cost, point-of-care DNA test for HPV infections that was invented at Rice University delivers results in 45 minutes and requires just two pieces of equipment, a
World medicine December 05,2023
DNA test could broaden access to cervical cancer screening

DNA test could broaden access to cervical cancer screening

by Jade Boyd,Rice UniversityA low-cost, point-of-care DNA test for HPV infections that was invented at Rice University delivers results in 45 minutes and requires just two pieces of equipment, a
World medicine December 05,2023
CRISPR studies identify many promising therapeutic targets for multiple myeloma

CRISPR studies identify many promising therapeutic targets for multiple myeloma

byDana-Farber Cancer InstituteComparative analysis of CERES scores for MM preferential dependencies in MM vs other hematologic malignancies vs. solid tumors. Results are presented in a manner si
World medicine December 05,2023
CRISPR studies identify many promising therapeutic targets for multiple myeloma

CRISPR studies identify many promising therapeutic targets for multiple myeloma

byDana-Farber Cancer InstituteComparative analysis of CERES scores for MM preferential dependencies in MM vs other hematologic malignancies vs. solid tumors. Results are presented in a manner si
World medicine December 05,2023
Guidance on clinical management of CHEK2 pathogenic variants and cancer risks

Guidance on clinical management of CHEK2 pathogenic variants and cancer risks

by American College of Medical Genetics and GenomicsCases illustrating CHEK2 testing in practice. CHEK2 case #2 is a 35-year-old female who was originally diagnosed at age 33 years with stage 2 breast
World medicine December 05,2023
Guidance on clinical management of CHEK2 pathogenic variants and cancer risks

Guidance on clinical management of CHEK2 pathogenic variants and cancer risks

by American College of Medical Genetics and GenomicsCases illustrating CHEK2 testing in practice. CHEK2 case #2 is a 35-year-old female who was originally diagnosed at age 33 years with stage 2 breast
World medicine December 05,2023
More News
Week’s Top
Podcasts
... Health spending has been rising across rich countries with different systems ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... At what age do people experience depression for the first time? Depression can affect people over long periods of their lives. Some people experience this condition continuously, while for others, it occu...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com